Cargando…

Glulisine Versus Human Regular Insulin in Combination With Glargine in Noncritically Ill Hospitalized Patients With Type 2 Diabetes: A randomized double-blind study

OBJECTIVE: To compare the efficacy and safety of the rapid-acting insulin analog glulisine and regular insulin in hyperglycemic hospitalized patients. RESEARCH DESIGN AND METHODS: A total of 180 hospitalized patients with type 2 diabetes received either glulisine (n = 88) or regular insulin (n = 92)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meyer, Christian, Boron, Anna, Plummer, Elena, Voltchenok, Marina, Vedda, Rosemarie
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2992177/ https://www.ncbi.nlm.nih.gov/pubmed/20805258 http://dx.doi.org/10.2337/dc10-0957

Ejemplares similares

Insulin glulisine in the management of diabetes
por: Yamada, Satoru
Publicado: (2009)

PSUN227 A retrospective comparison of Basal Bolus using Glargine U-300 and Glulisine with Premix Insulin
por: Abraham, Santhosh, et al.
Publicado: (2022)

Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study
por: Takeshita, Yumie, et al.
Publicado: (2020)

Glargine insulin: an alternative to regular insulin for glycemic control in critically ill patients
por: Bhattacharyya, M, et al.
Publicado: (2007)

Glargine versus regular insulin protocol in feline diabetic ketoacidosis
por: Zeugswetter, Florian K., et al.
Publicado: (2021)

Immunologic Tolerance to the Insulin Analogue Glulisine
por: Ozaki, Nobuaki, et al.
Publicado: (2010)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Comparison of morning basal + 1 bolus insulin therapy (insulin glulisine + insulin glargine 300 U/mL vs insulin lispro + insulin glargine biosimilar) using continuous glucose monitoring: A randomized crossover study
por: Takeishi, Soichi, et al.
Publicado: (2017)

A Randomized Trial of Two Weight-Based Doses of Insulin Glargine and Glulisine in Hospitalized Subjects With Type 2 Diabetes and Renal Insufficiency
por: Baldwin, David, et al.
Publicado: (2012)

Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
por: Lamos, Elizabeth Mary, et al.
Publicado: (2015)

Insulin Glargine 300 U/mL and Insulin Glulisine Treatment in Patients with Type 2 Diabetes: A Non-Interventional Study of Effectiveness in Routine Clinical Practice
por: Hidvégi, Tibor, et al.
Publicado: (2020)

Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes
por: Kawaguchi, Yuji, et al.
Publicado: (2021)

Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized Patients
por: Mendez, Carlos E., et al.
Publicado: (2014)

The role of insulin glulisine to improve glycemic control in children with diabetes mellitus
por: Lih, Anna, et al.
Publicado: (2010)

Correlation between Basal Insulin Glargine Dose Required in Achieving Target Fasting Blood Glucose and Various Clinical and Laboratory Parameters in Hospitalized Noncritical Patients
por: Lakhani, Om J., et al.
Publicado: (2018)

Effectiveness and tolerability of treatment intensification to basal–bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study
por: Pfohl, Martin, et al.
Publicado: (2015)

Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month ‘proof-of-concept’ study
por: Owens, D R, et al.
Publicado: (2011)

Insulin Glulisine in Pregnancy – Experience from Clinical Trials and Post-marketing Surveillance
por: Doder, Zoran, et al.
Publicado: (2015)

Analysis of insulin glulisine at the molecular level by X-ray crystallography and biophysical techniques
por: Gillis, Richard B., et al.
Publicado: (2021)

Insulin Glulisine May Cause a Disease Resembling Insulin Autoimmune Syndrome: Case Report
por: Kawasaki, Maki, et al.
Publicado: (2013)

Therapeutic monitoring of amikacin and gentamicin in critically and noncritically ill patients
por: Kovačević, Tijana, et al.
Publicado: (2016)

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
Publicado: (2021)

Comparison of Glycemic Control between Continuous Regular Insulin Infusion and Single-dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients
por: Bhurayanontachai, Rungsun, et al.
Publicado: (2018)

Combining insulins for optimal blood glucose control in type 1 and 2 diabetes: Focus on insulin glulisine
por: Ulrich, Heather, et al.
Publicado: (2007)

Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study
por: Seufert, Jochen, et al.
Publicado: (2021)

Optimizing Insulin Glargine Plus One Injection of Insulin Glulisine in Type 2 Diabetes in the ELEONOR Study: Similar effects of telecare and conventional self-monitoring of blood glucose on patient functional health status and treatment satisfaction
por: Nicolucci, Antonio, et al.
Publicado: (2011)

Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan, Tri Juli Edi, et al.
Publicado: (2021)

Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients
por: Gonzalez-Gonzalez, Jose Gerardo, et al.
Publicado: (2013)

Insulin glargine overdose
por: Doğan, Fatma Sarı, et al.
Publicado: (2012)

Diabetic Ketosis Caused by the Insulin Analog Aspart–Induced Anti-Insulin Antibody: Successful Treatment With the Newest Insulin Analog Glulisine
por: Yanai, Hidekatsu, et al.
Publicado: (2011)

A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19
por: Shuto, Hisayuki, et al.
Publicado: (2020)

Randomized Trial of Anticoagulation Strategies for Noncritically Ill Patients Hospitalized With COVID-19
por: Stone, Gregg W., et al.
Publicado: (2023)

Efficacy and safety of switching to insulin glulisine from other rapid-acting insulin analogs in children with type 1 diabetes
por: Urakami, Tatsuhiko, et al.
Publicado: (2015)

A case of type 1 diabetes mellitus with which localized insulin allergy was markedly alleviated by switching to insulin glulisine
por: Watanabe, Kahori, et al.
Publicado: (2016)

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
por: Linnebjerg, Helle, et al.
Publicado: (2016)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Insulin glargine and the risk of cancer
por: Ahmed, FA
Publicado: (2010)

A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus
por: Rostami, Parastoo, et al.
Publicado: (2014)

Update on Glucose Management Among Noncritically Ill Patients Hospitalized on Medical and Surgical Wards
por: Gupta, Tina, et al.
Publicado: (2017)

Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
por: Bergenstal, R. M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_njt5n5nh262mhc7ogcddhtm1pe